Citable filing context

AMGN filing events and research context

Server-rendered

AMGN's research view summarizes recent SEC filing context, starting with management_change from May 20, 2026.

AMGN filing events and research context
FiledItemContext
May 20, 2026management_changeAmgen Inc. held its Annual Meeting, electing 12 directors and approving executive compensation.
May 19, 2026management_changeAMGN announced Peter H. Griffith's retirement as CFO and Thomas Dittrich's appointment as new CFO, effective September 1, 2026.
Apr 30, 2026earningsAmgen reported Q1 2026 financial results with revenues up 6% to $8.6B and non-GAAP EPS up 5% to $5.15.
Apr 30, 2026Guidance: capital_expenditures2.60 to not reported
Apr 30, 2026Guidance: gaap_eps15.62 to 17.10
Apr 30, 2026Guidance: gaap_tax_rate14.50 to 16.00
May 1, 2026mda_quarterlyAmgen's product sales and profitability face substantial pressure from evolving healthcare policies and market consolidation. The Inflation Reduction Act (IRA) significantly impacts products like ENBREL and Otezla through mandatory Medicare price setting, inflation-based rebates, and Part D redesign, with adverse effects projected to increase through the decade. State-level initiatives, such as Colorado's Prescription Drug Affordability Board (PDAB) setting a substantially lower Upper Payment Limit for ENBREL effective 2027, further intensify pricing challenges. Commercial payer consolidation, including large PBMs like CVS and United Health Group, increases negotiating leverage, leading to demands for deeper discounts and more restrictive formulary access for Amgen's medicines. Regulatory risks are also prominent. The FDA has proposed withdrawing TAVNEOS due to questions regarding study data and effectiveness, while accelerated approvals for products like LUMAKRAS face heightened scrutiny for confirmatory data. Global economic instability, geopolitical tensions, and supply chain disruptions, exacerbated by events like the Middle East conflict, increase operational costs and threaten international sales. Additionally, sophisticated and increasing cybersecurity threats, including those impacting third-party providers like Change Healthcare, pose ongoing risks to business operations and sensitive data integrity.
Feb 13, 2026businessAmgen is a global biotechnology pioneer engaged in the discovery, development, manufacturing, and delivery of innovative human therapeutics, operating as a single human therapeutics segment. Key revenue-generating products in 2025 included Prolia ($4.4 billion), Repatha ($3.0 billion), Otezla ($2.3 billion), ENBREL ($2.2 billion), EVENITY ($2.1 billion), and XGEVA ($2.1 billion). The company primarily serves the U.S. market, which generated $25.7 billion in product sales in 2025, with significant international sales, particularly in Europe. A major strategic move was the $27.8 billion acquisition of Horizon Therapeutics in October 2023, expanding Amgen's rare disease portfolio with medicines like TEPEZZA (for TED), KRYSTEXXA (for chronic refractory gout), and UPLIZNA (for neuromyelitis optica spectrum disorder). Amgen engages in collaborations, including with AstraZeneca for TEZSPIRE, UCB for EVENITY, and BeOne Medicines for oncology products in China. A collaboration with Kyowa Kirin for rocatinlimab is transitioning to Kyowa Kirin in early 2026. The company faces risks such as the $1.2 billion impairment of Otezla's intangible assets in 2025 due to Medicare price setting under the IRA, and potential future impairment for TAVNEOS following an FDA withdrawal request.

Source: SEC EDGAR filing text and events; period May 20, 2026; filed May 20, 2026.

Continue research

Keep researching AMGN

Follow same-sector companies and source explainers connected to the research view.

Browse Health Care

Related tickers

LLY
Lilly (Eli)
$1.02T
Health Care
Open company page →
JNJ
Johnson & Johnson
$558.88B
Health Care
Open company page →
ABBV
AbbVie
$393.91B
Health Care
Open company page →
UNH
UnitedHealth Group
$369.32B
Health Care
Open company page →
MRK
Merck & Co.
$295.00B
Health Care
Open company page →
AZN
ASTRAZENECA PLC
$281.75B
Health Care
Open company page →

Related explainers

Understanding 8-K filings

A factual guide to SEC Form 8-K current reports and the material company events they can disclose between quarterly filings.

Read explainer →
Reading a 10-Q

A factual guide to quarterly SEC Form 10-Q reports, how they differ from annual 10-K filings, and what readers can inspect first.

Read explainer →
S-1 and the IPO prospectus

A factual guide to Form S-1 registration statements and the disclosures companies provide before a public offering.

Read explainer →
Reading an SEC 10-K

A factual guide to the core 10-K sections investors use for company context: business description, risk factors, MD&A, financial statements, and segment disclosures.

Read explainer →